Track market-moving stories before they get noisy

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has closed an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the “Notes”). The Notes are unsecured and bear interest at a rate of 6.300% per year, payable semiannually, will mature on July 24, 2031, and may be redeemed in whole or in part at any time or from time to time at the Company's o.

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), today announced that it has priced an underwritten public offering of $325.0 million in aggregate principal amount of 6.300% notes due July 2031 (the “Notes”). The closing of the transaction is subject to customary closing conditions and the Notes are expected to be delivered and paid for on July 24, 2026. The Notes are unsecured and bear interest at a rate of 6.300% per y.

-

SAN MATEO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules,” “Hercules Capital,” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its second quarter 2026 financial results conference call for Thursday, July 30, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day.

All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Resources section of our website at investor.htgc.com. Please visit the website to test your connection before the webcast. Domestic callers can access the conference call toll free by dialing +1 (800) 267-6316. International callers can access the conference call by dialing +1 (203) 518-9783. All callers are asked to dial in 10-15 minutes prior to the call so that name and company information can be collected and to reference the conference ID HTGCQ226. For interested parties, an archived replay will be available on a webcast link located on the Investor Resources section of Hercules Capital's website.

About Hercules Capital, Inc.

Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $27 billion to over 700 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.

Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the “Adviser Subsidiary”), also maintains an asset management business through which it manages investments for external parties (“Adviser Funds”). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940.

Hercules’ common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol “HTGC.” In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE: HCXY).

More News From Hercules Capital, Inc.

Back to Newsroom

June 29, 2026 08:00 ET  | Source: 4D Molecular Therapeutics, Inc.

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that it has entered into a strategic credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) for up to $200 million.

“Our strong cash, cash equivalents and marketable securities position, excluding this strategic credit facility, is expected to continue to fund our planned operations into the second half of 2028. Access to this non-dilutive capital further increases our financial strength, providing the Company with strategic and operational flexibility,” said Kristian Humer, Chief Financial Officer of 4DMT. “The credit facility diversifies our capital structure, allowing us to focus on sustaining our execution momentum, growth planning across our innovative gene therapy pipeline and early commercial planning for 4D-150.”

“Hercules Capital is pleased to support 4DMT with a flexible financing solution as the Company advances 4D-150 through Phase 3 development and pre-commercial planning in wet AMD and DME,” said Lake McGuire, Managing Director at Hercules Capital, Inc. “This partnership reflects our commitment to backing innovative genetic medicines with the potential to transform treatment paradigms for patients with serious unmet needs.”

Under the terms of the agreement, 4DMT drew an initial $20 million at closing. An additional $30 million is available, at the Company’s option, through June 15, 2027, with an additional $100 million available upon the Company’s achievement of certain milestones, and the remaining $50 million available subject to final lender approval.

The Company’s cash, cash equivalents and marketable securities were $458 million as of March 31, 2026.

Leerink Partners served as the exclusive financial advisor to 4DMT on the strategic credit facility.

About 4DMT

4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.

All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.

Learn more at www.4DMT.com and follow us on LinkedIn.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and expressed statements regarding the therapeutic potential and clinical benefits of, as well as the plans, announcements and related timing for, the clinical development of the Company’s product candidates; the Company's expectations regarding financing alternatives and its anticipated cash runway; the availability of, and the Company’s ability to access or draw, additional capital under the credit facility; the achievement of the milestones, conditions or approvals required to access such additional capital; the expected non-dilutive nature and benefits of the credit facility; and the Company’s financial, strategic and operational flexibility. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements, except as may be required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Contacts:

Media:

Jenn Gordon
dna Communications
[email protected]

Investors:

Julian Pei
Head of Investor Relations and Strategic Finance
[email protected]

Hercules Capital is trading at a 30% premium to NAV, down from 72% in 2024, reflecting compressed sentiment around technology-focused BDCs. HTGC is paying out a 12.1% dividend yield, with a $0.40 base and a $0.07 supplemental quarterly dividend. The base dividend was 120% covered by first-quarter net investment income. Portfolio credit quality remains robust, with nonaccruals at fair value at just 0.1% of the total investment portfolio as of the end of the first quarter.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Hercules Capital (HTGC - Free Report) .

Hercules Capital currently has an average brokerage recommendation (ABR) of 1.70, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 10 brokerage firms. An ABR of 1.70 approximates between Strong Buy and Buy.

Of the 10 recommendations that derive the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 60% and 10% of all recommendations.

Brokerage Recommendation Trends for HTGC

Check price target & stock forecast for Hercules Capital here>>>

While the ABR calls for buying Hercules Capital, it may not be wise to make an investment decision solely based on this information. Several studies have shown limited to no success of brokerage recommendations in guiding investors to pick stocks with the best price increase potential.

Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.

This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.

Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision.

Zacks Rank Should Not Be Confused With ABRIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.

Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.

Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.

In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.

In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.

Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.

Should You Invest in HTGC?In terms of earnings estimate revisions for Hercules Capital, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $1.93.

Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Hercules Capital. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Hercules Capital.

Hercules Capital (HTGC - Free Report) ended the recent trading session at $15.65, demonstrating a +1.03% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.57%. Elsewhere, the Dow saw an upswing of 0.64%, while the tech-heavy Nasdaq depreciated by 1.15%.

Heading into today, shares of the specialty finance company had gained 0.58% over the past month, lagging the Finance sector's gain of 4.57% and the S&P 500's gain of 2.14%.

Market participants will be closely following the financial results of Hercules Capital in its upcoming release. The company's upcoming EPS is projected at $0.5, signifying steadiness compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $148.9 million, up 8.32% from the prior-year quarter.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $1.93 per share and a revenue of $588.4 million, representing changes of +1.05% and +10.5%, respectively, from the prior year.

Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Hercules Capital. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Hercules Capital holds a Zacks Rank of #3 (Hold).

In terms of valuation, Hercules Capital is currently trading at a Forward P/E ratio of 8.03. This signifies a discount in comparison to the average Forward P/E of 8.06 for its industry.

The Financial - SBIC & Commercial Industry industry is part of the Finance sector. This industry, currently bearing a Zacks Industry Rank of 207, finds itself in the bottom 16% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hercules Capital, Inc. (NYSE: HTGC) between May 1, 2025 and February 27, 2026, inclusive (the “Class Period”), of the important May 19, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Hercules Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Hercules Capital class action, go to https://rosenlegal.com/submit-form/?case_id=56968 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Hercules Capital overstated the due diligence with which it conducted its deal sourcing and/or loan origination process; (2) Hercules Capital overstated the due diligence with which it conducted its portfolio valuation process; (3) Hercules Capital reported misclassified portfolio investments; (4) as a result of the foregoing, Hercules Capital overstated and/or misrepresented its portfolio valuations; and (5) as a result of the foregoing, defendants’ positive statements about Hercules Capital’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Hercules Capital class action, go to https://rosenlegal.com/submit-form/?case_id=56968 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hercules Capital (HTGC) To Contact Him Directly To Discuss Their Options

If you purchased or acquired Hercules Capital securities between May 1, 2025 and February 27, 2026, and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.

Click here to participate in the action.

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) --

What’s Happening?

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Hercules Capital, Inc. (“Hercules Capital” or the “Company”) (NYSE:HTGC) in the The United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Hercules Capital securities between May 1, 2025 and February 27, 2026, both dates inclusive (the “Class Period”).Investors have until May 19, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. What are the Allegation Details?

According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Hercules Capital overstated the due diligence with which it conducted its deal sourcing and/or loan origination process; (2) Hercules Capital overstated the due diligence with which it conducted its portfolio valuation process; (3) Hercules Capital reported misclassified portfolio investments; (4) as a result of the foregoing, Hercules Capital overstated and/or misrepresented its portfolio valuations; and (5) as a result of the foregoing, defendants’ positive statements about Hercules Capital’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. What are the Next Steps?

If you purchased or otherwise acquired Hercules Capital shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising.  Prior results do not guarantee similar outcomes.

Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.

Melissa Fortunato, Esq.
(212) 355-4648
[email protected]
www.bespc.com

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hercules Capital To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Hercules Capital between May 1, 2025 and February 27, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - May 18, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hercules Capital, Inc. ("Hercules Capital" or the "Company") (NYSE: HTGC) and reminds investors of the May 19, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company overstated the due diligence with which it conducted its deal sourcing and/or loan origination process; (2) the Company overstated the due diligence with which it conducted its portfolio valuation process; (3) the Company reported misclassified portfolio investments; (4) as a result of the foregoing, the Company overstated and/or misrepresented its portfolio valuations; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On February 27, 2026, Hunterbrook Media published a report stating that, "according to a former Hercules analyst who worked on deal sourcing" the Company's process for deal sourcing essentially amounted to "[g]o[ing] on the website for Google Ventures and just see what they invest in and just copy it." The report stated, according to a former employee, deal sourcing managers "don't want anything else," and essentially just rely on other investors to have done due diligence, instead of doing their own.

The report continued, revealing that, "once Hercules makes the loans, the valuation process itself may warrant scrutiny," as "[a] former member of Hercules' finance team described a small, overstretched team with few checks in place." The report revealed the valuations team "consisted of just four people in a single reporting line responsible for dozens of companies," with "few checks or cross-team review."

The report also alleged that Hercules Capital underrepresents its significant software debt exposure in part, by "assign[ing] certain businesses that describe themselves as software companies to categories outside of software." The report also cast doubt on to the Company's book value, which marks its software debt "at 100 cents on the dollar" despite "billions worth of [software] debt across the industry falling into distressed territory."

On this news, Hercules Capital's stock price fell $1.22, or 7.9%, to close at $14.21 per share on February 27, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Hercules Capital's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Hercules Capital class action, go to www.faruqilaw.com/HTGC or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297835

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

LOS ANGELES, May 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hercules Capital, Inc., (“Hercules” or the "Company") (NYSE: HTGC) investors of a class action on behalf of investors that bought securities between May 1, 2025 and January 27, 2026, inclusive (the “Class Period”). Hercules investors have until May 21, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/hercules-capital-inc. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On February 27, 2026, Hunterbrook Media published a report stating that, “according to a former Hercules analyst who worked on deal sourcing” the Company’s process for deal sourcing essentially amounted to “[g]o[ing] on the website for Google Ventures and just see what they invest in and just copy it.” The report stated, according to a former employee, deal sourcing managers “don’t want anything else,” and essentially just rely on other investors to have done due diligence, instead of doing their own.

The report continued, revealing that, “once Hercules makes the loans, the valuation process itself may warrant scrutiny,” as “[a] former member of Hercules’ finance team described a small, overstretched team with few checks in place.” The report revealed the valuations team “consisted of just four people in a single reporting line responsible for dozens of companies,” with “few checks or cross-team review.”

The report also alleged that Hercules Capital underrepresents its significant software debt exposure in part, by “assign[ing] certain businesses that describe themselves as software companies to categories outside of software.” The report also cast doubt on to the Company’s book value, which marks its software debt “at 100 cents on the dollar” despite “billions worth of [software] debt across the industry falling into distressed territory.”

On this news, Hercules Capital’s stock price fell $1.22, or 7.9%, to close at $14.21 per share on February 27, 2026, on unusually heavy trading volume.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) --

HERCULES CAPITAL INC. (NYSE: HTGC):

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Hercules Capital Inc. (NYSE: HTGC). The investigation concerns whether certain officers and directors of Hercules Capital breached their fiduciary duties owed to the Company.

If you purchased Hercules Capital Inc. (NYSE: HTGC) shares prior to May 1, 2025, and continue to hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/hercules-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085. You may be able to seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever.

WHY? According to a recently filed federal securities fraud class action complaint, Hercules Capital Inc. (NYSE: HTGC), through certain of its officers, made materially false and misleading statements or failed to disclose that: (1) Hercules Capital overstated the due diligence with which it conducted its deal sourcing and/or loan origination process; (2) Hercules Capital overstated the due diligence with which it conducted its portfolio valuation process; (3) Hercules Capital reported misclassified portfolio investments; (4) as a result of the foregoing, Hercules Capital overstated and/or misrepresented its portfolio valuations; and (5) as a result of the foregoing, defendants' positive statements about Hercules Capital's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

WHAT CAN YOU DO NOW? If you purchased Hercules Capital Inc. (NYSE: HTGC) shares prior to May 1, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever. For more information, please visit https://grabarlaw.com/the-latest/hercules-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085.

$HTGC #HTGC #HerculesCapital

LKQ CORPORATION (NASDAQ: LKQ):

WHAT IS HAPPENING? Grabar Law Office is investigating potential claims on behalf of investors of LKQ Corporation (NASDAQ: LKQ). The investigation concerns whether certain officers of the company have breached their fiduciary duties they owed to the company.

If you purchased LKQ Corporation (NASDAQ: LKQ) shares prior to February 27, 2023, and still hold shares today, you should visit https://grabarlaw.com/the-latest/lkq-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever.

WHY? A recently filed federal securities class action alleges that LKQ Corporation (NASDAQ: LKQ), through certain of its senior executives, misled investors regarding the performance and risks associated with its $2.1 billion acquisition of Uni-Select, including the FinishMaster business. According to the securities fraud complaint, LKQ Corporation, through certain of its officers, made materially false and misleading statements and failed to disclose that: (1) FinishMaster was losing major customers even before the acquisition closed; (2) the business was unable to maintain market share amid increasing competition; (3) integration efforts were not producing the expected revenue or margin benefits; and (4) competitive pricing pressure was eroding profitability. As a result, it is alleged that LKQ’s reported financial strength and growth prospects were materially overstated. Investors only began to learn the truth through a series of disclosures between April 2024 and July 2025, when LKQ cut financial guidance multiple times; reported missed revenue and margin targets; admitted that FinishMaster had been losing customers since before the acquisition; and disclosed ongoing market share losses due to competitive pricing pressure.

WHAT CAN YOU DO NOW? If you have held LKQ Corporation (NASDAQ: LKQ) shares since prior to February 27, 2023, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever. Visit https://grabarlaw.com/the-latest/lkq-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085 to learn more. $LKQ #LKQ #LKQCorporation

NEW ERA ENERGY & DIGITAL, INC. (NASDAQ: NUAI):

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of New Era Energy & Digital, Inc. (NASDAQ: NUAI). The investigation concerns whether New Era and certain of its officers and directors breached their fiduciary duties owed to the Company.

If you purchased New Era Energy & Digital, Inc. (NASDAQ: NUAI) shares on or near the Company’s November 6, 2024 IPO, and still hold shares today, please visit https://grabarlaw.com/the-latest/newera-shareholder-investigation-2/ contact Joshua H. Grabar at [email protected], or call 267-507-6085. You may be able to seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever.

WHY? According to a recently filed federal securities fraud class action complaint, New Era (NASDAQ: NUAI) and certain of its officers allegedly made false and misleading statements concerning the Company’s Texas Critical Data Centers project, permitting progress, environmental liabilities, and related-party oil and gas transactions. The complaint alleges that New Era overstated its progress in obtaining regulatory permits and advancing its purported flagship Texas Critical Data Centers project, while publicly touting “tangible progress across all fronts including engineering, permitting, regulatory filings, and land expansion.” According to the complaint, the Company also represented to investors that it was making substantial progress toward a large-scale AI and high-performance computing data center campus in West Texas.

On December 12, 2025, however, Fuzzy Panda Research published a report alleging that New Era’s AI pivot was largely a “fantasy,” and that despite Company representations regarding permitting progress, “no applications have even been submitted” for required construction and environmental permits. The same report further alleged that a substantial number of New Era’s gas wells had been acquired from bankrupt entities tied to Company insiders and accused management of engaging in financial practices designed to enrich insiders while avoiding environmental cleanup obligations. On this news, New Era stock fell approximately 6.9% on December 12, 2025.

Then, on December 29, 2025, reports emerged that the New Mexico Attorney General had filed suit against New Era, its subsidiary Solis Partners, LLC, and Company CEO Everett Willard Gray II, alleging a “fraudulent oil-and-gas scheme” involving self-dealing transactions, shell entities, and strategic bankruptcies designed to evade plugging and remediation obligations for inactive wells. According to the complaint, the alleged scheme involved transferring wells among affiliated entities while leaving environmental liabilities behind in bankruptcy proceedings. On this news, New Era stock fell an additional 41%, closing at $2.69 per share on December 29, 2025.

WHAT CAN YOU DO NOW? If you purchased or otherwise acquired New Era Energy & Digital, Inc. (NASDAQ: NUAI) shares prior to November 6, 2024, and continue to hold shares today, you may have standing to seek corporate governance reforms, the return of funds back to the Company, and a court-approved incentive award at no cost to you whatsoever. Visit https://grabarlaw.com/the-latest/newera-shareholder-investigation-2/, email Joshua Grabar at [email protected], or call us at 267-507-6085.

#NewEraEnergy #NUAI $NUAI

POWER SOLUTIONS INTERNATIONAL, INC. (NASDAQ: PSIX):

WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Power Solutions International, Inc. (NASDAQ: PSIX). The investigation concerns whether Power Solutions and certain of its executives breached their fiduciary duties.

If you purchased Power Solutions International, Inc. (NASDAQ: PSIX) shares prior to May 8, 2025, please visit https://grabarlaw.com/the-latest/psix-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085. You can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever.

WHY? According to a recently filed federal securities fraud class action complaint, Power Solutions (NASDAQ: PSIX); through certain of its officers, failed to disclose to investors: (1) the Company overstated its ability to capture sales demand for its power systems solutions, particularly within the data center market; (2) the Company understated the impact of its enhancements to manufacturing capacity to meet demand within the data center market, including the expected costs and the nature of the related “inefficiencies”; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. 

WHAT CAN YOU DO NOW? If you purchased or otherwise acquired Power Solutions International, Inc. (NASDAQ: PSIX) securities prior to May 8, 2025, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you whatsoever. Visit https://grabarlaw.com/the-latest/psix-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085 to learn more.   #PSIX $PSIX #PowerSolutions

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel:  267-507-6085
Email: [email protected]

NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hercules Capital, Inc. (“Hercules” or the “Company”) (NYSE: HTGC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

The class action concerns whether Hercules and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have until May 19, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Hercules securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.   

[Click here for information about joining the class action]  

On February 27, 2026, Hunterbrook Media published a short report entitled “The Myth of Hercules Capital.” The report alleged that, “according to a former Hercules analyst who worked on deal sourcing” the Company’s process for deal sourcing essentially amounted to “[g]o[ing] on the website for Google Ventures and just see what they invest in and just copy it.” The report stated, according to a former employee, deal sourcing managers “don’t want anything else,” and essentially just rely on other investors to have done due diligence, instead of doing their own. The report continued, revealing that, “once Hercules makes the loans, the valuation process itself may warrant scrutiny,” as “[a] former member of Hercules’ finance team described a small, overstretched team with few checks in place.” This second former employee revealed the valuations team “consisted of just four people in a single reporting line responsible for dozens of companies,” with “few checks or cross-team review.” The former employee noted this was contrary to how things were done at other public companies where, in contrast “[t]here is a strong push to do things the right way, to reinvent, to make sure that we’re double-checking, triple-checking.” The report stated the former employee found this was not the case at Hercules. The report also alleged that Hercules Capital underrepresents its significant software debt exposure. The report stated the Company does this, in part, by “assign[ing] certain businesses that describe themselves as software companies to categories outside of software.” The report also cast doubt on to the Company’s book value, which marks its software debt “at 100 cents on the dollar” despite “billions worth of [software] debt across the industry falling into distressed territory.” 

Following publication of the Hunterbrook report, Hercules’s stock price fell $1.22 per share, or 7.91%, to close at $14.21 per share on February 27, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT: 
Danielle Peyton 
Pomerantz LLP 
[email protected] 
646-581-9980 ext. 7980

A month has gone by since the last earnings report for Hercules Capital (HTGC - Free Report) . Shares have lost about 7.4% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Hercules Capital due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Hercules Capital Q1 Earnings Beat Estimates on Record New CommitmentsHercules Capital’s first-quarter 2026 net investment income of 48 cents per share beat the Zacks Consensus Estimate by a penny. The bottom line grew 6.7% from the year-ago quarter.

Results primarily benefited from an increase in the total investment income and record new commitments. The balance sheet position remained decent. However, a rise in operating expenses was a headwind.

Net investment income was $88.1 million, up 13.8% year over year.

Total Investment Income Improves, Expenses RiseTotal investment income in the quarter was a record $141.5 million, rising 22.5% from the year-ago quarter. The top line surpassed the Zacks Consensus Estimate of $138 million.

Total quarterly gross operating expenses increased 28.1% to $58.1 million. The rise was due to an increase in almost all cost components except for general and administrative expenses.

Portfolio Value & New Commitments SolidThe fair value of Hercules Capital’s total investment portfolio was $4.72 billion as of March 31, 2026.

In the first quarter, the company delivered a record $1.81 billion in gross new debt and equity commitments and $706.4 million in total new funding. It realized early loan repayments of $225.8 million. This, along with scheduled amortization of $1.7 million, led to total debt repayments of $227.5 million.

Balance Sheet Position DecentAs of March 31, 2026, Hercules Capital’s net asset value was $11.90 per share, down from $12.13 as of Dec. 31, 2025.

As of March 31, 2026, the company had $454.5 million in liquidity, including $42.4 million of unrestricted cash and cash equivalents, and $412.1 million in credit facilities.

At the end of the quarter, the weighted average cost of borrowings, comprising interest and fees, was 5.1%, up from 4.9% at the end of the prior-year quarter.

OutlookManagement expects prepayments to be in the range of $350-$500 million in the second quarter of 2026.

The company expects core yields in the second quarter of 2026 to be 12-12.5%.
Originations are expected to moderate in the second quarter.

Interest expenses in the second quarter are expected to increase compared to the previous quarter based on debt portfolio growth.

The company expects gross selling, general and administrative (SG&A) expenses to be in the $27.5-$28.5 million range in the second quarter of 2026.

A Registered Investment Advisor (RIA) expense allocation of roughly $4.5 million is expected to be incurred in the second quarter.

The company expects a quarterly dividend from the RIA of approximately $2-$2.5 million per quarter in 2026.

How Have Estimates Been Moving Since Then?Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.

VGM ScoresAt this time, Hercules Capital has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock has a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook Hercules Capital has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

-- $135 million equity financing with participation from leading specialist investors, corporate investors, and long-term growth partners, including Wellington Partners, JIC Venture Growth Investments (JIC VGI), Founders Fund, Narya Capital, Eisai Co., Ltd., and other select institutional investors
-- Up to $165 million in flexible, non-dilutive capital, including $110 million senior-secured debt facility and $55 million of royalty financing with Hercules Capital, Inc.
-- Financing will support investments in commercial readiness activities for adrabetadex ahead of its November 17, 2026, Prescription Drug User Fee Act (PDUFA) target action date. This will include the development of a long-term patient access and family support program designed to reduce the burden for those living with infantile-onset Niemann-Pick disease, type C (I-NPC) throughout their treatment journey.
-- This transaction positions Beren to become financially self-sustaining through the potential commercialization of adrabetadex, while providing the flexibility to invest in long-term growth initiatives

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Beren Therapeutics P.B.C., the parent company of Mandos LLC and a leader in cholesterol trafficking biology and cyclodextrin-based therapeutics, today announced it has secured $300 million in combined financing.

The financing includes a $135 million equity financing alongside up to $165 million in a strategic financing facility with Hercules Capital, Inc. (NYSE: HTGC) across a senior secured debt and royalty structure. Capital will support Beren’s growth strategies, including the potential U.S. commercial launch for adrabetadex to treat I-NPC and investments in patient access infrastructure and family support resources.

“I-NPC reshapes family life. Families have consistently told us that their burden extends far beyond the availability of therapies, and that there remains a substantial unmet need for long-term support as families navigate diagnosis, treatment decisions, specialist care, reimbursement, and changing needs over a multi-decade journey with this disease,” said Jason Camm, Founder and Chief Executive Officer at Beren. “Our vision is not only to develop new treatment options, but also to help address the broader challenges families face throughout their journey. We are pleased to be joined by a world-class group of investors who share that vision and our conviction in what may now be possible for this community.”

I-NPC is the most severe, rapidly progressive form of NPC, a rare, always fatal, pediatric neurodegenerative disease characterized by impaired intracellular cholesterol trafficking. If approved, adrabetadex would represent a first-in-class, disease-modifying treatment for I-NPC and be the only therapy approved to directly act on the accumulated intracellular cholesterol that drives the disease. The U.S. Food and Drug Administration (FDA) accepted Beren’s New Drug Application for the investigational therapy, adrabetadex, which is under Priority Review with a PDUFA target action date of November 17, 2026.

Use of proceeds

Financing proceeds will support a comprehensive set of programs in anticipation of a potential approval and launch of adrabetadex that best provides access and meaningful support to the NPC community, including:

Accelerating diagnosis to support early intervention Providing a single point of contact for families Ensuring local access to sites of care Generating longitudinal real-world evidence and shared learning Strengthening peer-to-peer learning and community connectivity “Infantile-onset NPC is a disease that takes children from their families faster than almost any parent can comprehend. For decades, families in our community have lived with the day-to-day complexity of caring for a child with a progressive neurodegenerative disease – coordinating across specialists, navigating insurance, and managing care that touches every part of family life,” noted Garland Alvey, Executive Director and Founder of ‘AbbyStrong Fights NPC,’ Board Member of the National Niemann-Pick Disease Foundation, and Trustee of the International Niemann-Pick Disease Registry. “Continued commitment from companies and investors to advance new therapies and to build the support systems families actually need is what gives our community reason to believe the path forward keeps getting better.”

Financial transactions

The $135 million equity financing brought together a concentrated group of specialist healthcare investors, long-term growth partners, and strategic investors, including Wellington Partners, JIC Venture Growth Investments (JIC VGI), Founders Fund, Narya Capital, Eisai Co., Ltd., and other select institutional investors. The financing supports Beren’s long-term global strategy, including preparations for the potential commercial launch of adrabetadex and continued investment in patient access, family support, and care infrastructure for the infantile-onset NPC community.

Concurrent with the equity financing, Beren entered a $165 million non-dilutive financing agreement with Hercules Capital, Inc. to provide the company greater financial flexibility at a lower blended cost of capital, comprised of:

Up to $110 million in term loans based on regulatory and revenue milestones, of which $30 million is currently drawn A $55 million royalty financing to be funded upon FDA approval of adrabetadex. The royalty financing carries a 7.5% royalty on U.S. net sales and a 5% royalty on net sales outside the U.S. of adrabetadex, up to a 1.75x cap through 2031 and with the ability to redeem at a lower multiple in the first two years “Hercules is proud to partner with Beren as they prepare for the potential launch of adrabetadex for children with infantile-onset NPC. Jason and the Beren team have built a company with deep conviction in the science and a clear-eyed plan to ensure this therapy reaches all families who need it. We are pleased to provide the capital to support that work, and Beren’s continued evolution over the coming years,” said Cristy Barnes, Managing Director at Hercules Capital.

Morgan Stanley & Co. LLC acted as sole structuring agent on the transactions. Wilson Sonsini Goodrich & Rosati served as legal advisor to Beren, and Latham & Watkins advised Hercules.

About Infantile-Onset Niemann-Pick Disease, Type C

Niemann-Pick disease, type C (NPC) is a rare, autosomal-recessive, severe, heterogeneous, neurodegenerative disorder caused by pathogenic variants in the NPC1 (~95% of cases) or NPC2 genes, leading to impaired intracellular cholesterol trafficking resulting in progressive neurological decline and premature mortality. Infantile-onset NPC (I-NPC) refers to NPC in infants and children who first experience neurological symptoms <6 years of age. Earlier neurological onset is associated with more rapid progression and poorer prognosis, with mean ages of death of ~5.6 years for early infantile-onset (age of neurological onset <2 years) and ~13.4 years for late-infantile onset (2 to <6 years).

About Adrabetadex

Adrabetadex is a proprietary mixture of 2-hydroxypropyl-β-cyclodextrin isomers under investigation as a treatment for Niemann-Pick disease, type C (NPC). The data suggest that by re-establishing intracellular cholesterol trafficking, adrabetadex is designed to directly address the underlying pathology of NPC. Data from clinical trials and expanded access programs suggest that adrabetadex is generally well tolerated. The main adverse events associated with adrabetadex include hearing impairment that can be managed with hearing aids when necessary, and post-dose fatigue and/or ataxia.

The U.S. Food and Drug Administration (FDA) granted adrabetadex Breakthrough Therapy Designation. In February 2026, the FDA accepted Beren Therapeutics’ New Drug Application (NDA) for adrabetadex in infantile-onset NPC for Priority Review. The agency assigned the NDA a Prescription Drug User Fee Act target action date of November 17, 2026. Adrabetadex has not been approved by the FDA or any other health authority at this time.

About Beren Therapeutics P.B.C.

Beren Therapeutics P.B.C. is a founder-led biotechnology company pioneering the discovery, development, and commercialization of cyclodextrin-based therapeutics for conditions characterized by defective cholesterol trafficking. Beren’s first program, adrabetadex, is under U.S. Food and Drug Administration review with a Prescription Drug User Fee Act target action date of November 17, 2026, for the treatment of infantile-onset Niemann-Pick disease, type C (I-NPC). Beren and its subsidiary Mandos LLC have supported the NPC community since 2021 through an Expanded Access Program and are preparing for the U.S. commercial launch of adrabetadex, if approved, with a comprehensive set of patient access and family support programs.

Beren’s public benefit purpose is to discover, develop, and deliver novel therapies that provide optimal benefit for patients, and to do so by integrating the needs of patients, caregivers, clinicians, and health systems from the beginning of the development process and maintaining a long-term focus on delivering meaningful therapies and access.

Beren is headquartered in Thousand Oaks, Calif. To learn more about Beren, the adrabetadex program, and Beren’s cholesterol-trafficking focused therapeutic strategy, visit the company’s website at: https://www.BerenTx.com/ or follow Beren on LinkedIn.

About Hercules Capital

Hercules Capital, Inc. (NYSE: HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology and life sciences industries. Since inception (December 2003), Hercules has committed more than $27 billion to over 700 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. To learn more, visit htgc.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements regarding the U.S. Food and Drug Administration’s review of the New Drug Application for adrabetadex; the timing and outcome of regulatory review; the potential for adrabetadex to provide clinical benefit or to address the underlying pathology of Niemann-Pick disease, type C; the potential for approval or commercialization; the ability to continue providing access through expanded access; and Beren’s plans to expand its pipeline. Actual results may differ materially due to risks and uncertainties including those associated with clinical development, regulatory review, manufacturing, safety and efficacy outcomes, and other factors.

More News From Beren Therapeutics P.B.C.